Login
Navigate Fool.com
Will AKRX beat
the market?

Akorn, Inc.

NASDAQ: AKRX

Community Rating: 4 Stars: Favorite

24.29 0.25 (1.04%)

REAL-TIME: Last trade at

Extended Hours: $24.29 $0.00 (0.00%)
Quote as of (NASDAQ)


company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $24.11
Previous Close $24.04
Daily Range $23.51 - $24.49
52-Week Range $12.86 - $28.00
Market Cap $2.3B
P/E Ratio 52.26
Dividend (Yield) $0.00 (0.0%)
Volume 464,748
Average Daily Volume 903,029
Current FY EPS $0.77

How do you think AKRX
will perform against the market?

Top AKRX Bull/Bear Pitches

 

HealthcareGuy (< 20)
Submitted December 29, 2010

Akorn, is a generic pharma company that has been remade by successful healthcare turnaround investor John Kapoor (Chariman of the Board). The major catalyst for this name, will be FDA approval of AKR … More

1 Replies Reply Report this Post
 

OriginalBarnacle (< 20)
Submitted August 23, 2007

P/b = 10.2 <br /><br />P/S = 12.7 <br /><br />No earnings <br /><br />Margins are worse with increasing inventory. <br /><br />Price change over 106% <br /><br />

0 Replies Reply Report this Post

News & Commentary

Why Akorn, Inc. Shares Were Cracked

Akorn shares tumble after the company reports its fourth-quarter earnings results. Is this dip the perfect buying opportunity or all the more reason to keep your distance?

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

Interesting AKRX Put And Call Options For May 17th

Ten Top Biotech Merger and Partnership Candidates

Mid-Day Market Update: Akorn Shares Slip After Downbeat Outlook; Dendreon Gains

Mid-Morning Market Update: Markets Open Lower; Tyco To Sell South Korean Security Business For $1.93

Mid-Morning Market Update: Markets Open Lower; Tyco To Sell South Korean Security Business For $1.93B

Why You Should Watch Sanofi, Salix, Akorn, and Isis Today

Sanofi, Salix, Akorn, and Isis are four stocks you should be watching today. Here’s why.

Akorn Acquires U.S. Rights to Trio of Merck Eye Treatments

The company will pay nearly $53 million in the deal.

Drugmaker Akorn Becoming Mighty Oak In Hi-Tech Merger

The New Leader in Ophthalmology

Analyzing the impact of Akorn's acquisition of Hi-Tech.

See More AKRX News...

Sector

Healthcare

Industry

Drugs

Akorn, Inc. (AKRX) Description

The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. Website: http://www.akorn.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks